Gapping up
In reaction to strong earnings/guidance: ANFI +11.1%, ARCP +6.9%, PTLA +4.5%, SSYS +3.9%, AMBC +2.5%, EVEP +1.6%, ECYT +1.6%, MHR +1.5%, ENDP +1.3%, NCT +1.2%, TCAP +0.5%
M&A news: MVNR +23.1% (to be acquired by Mitel (MITL) in a cash and stock deal valued at ~$560 mln, or $17.94 per share), FSL +7.7% (Freescale Semi and NXPI to merge), BSX +1.2% (entered into a definitive agreement with Endo International (ENDP) to acquire the American Medical Systems urology portfolio for $1.6 bln in up-front cash and a potential additional $50 million milestone based on 2016 sales), .
Select EU financial related names showing strength: RBS +2%, LYG +1.2%, BCS +0.9%
Other news: ATHX +19.7% (Athersys and Chugai enter license agreement and collaboration to develop MultiStem Cell Therapy for ischemic stroke in japan), ONCY +19.2% (announces receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube), OHRP +13.8% (announces additional positive anatomic data from the OHR-102 IMPACT study interim analysis),NXPI +11.7% (Freescale Semi and NXPI to merge), ACST +10.9% (announces full data for phase II TRIFECTA Trial ), TCPI +7.7% (issues statement on recent litigation; co has voluntarily chosen to conduct additional levels of quality control on its products), SCOK +3.8% (to produce hydrogen at Syngas Facilities for sale to Shenma Industry Co), STM +2.7% (announced that ST was providing micro-mirrors and control devices for Perceptual Computing initiatives at Intel (INTC)), ALKS +1.8% (announces new drug candidate, ALKS 7119, for treatment of Alzheimer's Agitation, Depression and other CNS Diseases), FEYE +1.4% (announced a new product integration with Samsung to enhance enterprise risk management on Samsung KNOX-enabled devices. ), TCON+1.4% (announces positive Phase 1b results for TRC105 in combination with Inlyta), DVAX +1.4% (announces that the independent Data and Safety Monitoring Board has completed its second prespecified review and has recommended that the study continue unchanged), AMGN +1.3% (Amgen's Phase 3 Head-to-Head ENDEAVOR Study demonstrates superiority of Kyprolis over Velcade in patients with relapsed multiple myeloma), BTU +1.3% (announces offering of $1.0 billion in senior secured second lien notes, in a private placement )
Analyst comments: URI +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley ), ZIOP +1.5% ( target raised to $14 from $11 at Mizuho), JKHY +1.2% (upgraded to Outperform at Oppenheimer), ALK +0.9% (upgraded to Buy at Stifel), TWTR +0.6% (initiated with a Buy at Axiom Capital)
In reaction to strong earnings/guidance: ANFI +11.1%, ARCP +6.9%, PTLA +4.5%, SSYS +3.9%, AMBC +2.5%, EVEP +1.6%, ECYT +1.6%, MHR +1.5%, ENDP +1.3%, NCT +1.2%, TCAP +0.5%
M&A news: MVNR +23.1% (to be acquired by Mitel (MITL) in a cash and stock deal valued at ~$560 mln, or $17.94 per share), FSL +7.7% (Freescale Semi and NXPI to merge), BSX +1.2% (entered into a definitive agreement with Endo International (ENDP) to acquire the American Medical Systems urology portfolio for $1.6 bln in up-front cash and a potential additional $50 million milestone based on 2016 sales), .
Select EU financial related names showing strength: RBS +2%, LYG +1.2%, BCS +0.9%
Other news: ATHX +19.7% (Athersys and Chugai enter license agreement and collaboration to develop MultiStem Cell Therapy for ischemic stroke in japan), ONCY +19.2% (announces receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube), OHRP +13.8% (announces additional positive anatomic data from the OHR-102 IMPACT study interim analysis),NXPI +11.7% (Freescale Semi and NXPI to merge), ACST +10.9% (announces full data for phase II TRIFECTA Trial ), TCPI +7.7% (issues statement on recent litigation; co has voluntarily chosen to conduct additional levels of quality control on its products), SCOK +3.8% (to produce hydrogen at Syngas Facilities for sale to Shenma Industry Co), STM +2.7% (announced that ST was providing micro-mirrors and control devices for Perceptual Computing initiatives at Intel (INTC)), ALKS +1.8% (announces new drug candidate, ALKS 7119, for treatment of Alzheimer's Agitation, Depression and other CNS Diseases), FEYE +1.4% (announced a new product integration with Samsung to enhance enterprise risk management on Samsung KNOX-enabled devices. ), TCON+1.4% (announces positive Phase 1b results for TRC105 in combination with Inlyta), DVAX +1.4% (announces that the independent Data and Safety Monitoring Board has completed its second prespecified review and has recommended that the study continue unchanged), AMGN +1.3% (Amgen's Phase 3 Head-to-Head ENDEAVOR Study demonstrates superiority of Kyprolis over Velcade in patients with relapsed multiple myeloma), BTU +1.3% (announces offering of $1.0 billion in senior secured second lien notes, in a private placement )
Analyst comments: URI +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley ), ZIOP +1.5% ( target raised to $14 from $11 at Mizuho), JKHY +1.2% (upgraded to Outperform at Oppenheimer), ALK +0.9% (upgraded to Buy at Stifel), TWTR +0.6% (initiated with a Buy at Axiom Capital)